The market likes the update however and I do too. Its been well said before, but the established EPP provision network in the USA and natural Vitiligo rollout synergies are an impressive and unusual facilitation of, instead of normal hurdles to, market entry of new treatments in the innovative bio-tech sphere. I still scratch my head on this company, already making good and growing revenues, cash flows and profits and only poised to improve and expand.
$36 million half yearly revenues, $14 million net profit, $200 million in hand and already growing revenues Your original undervaluation arguments only ring louder with a lower share price/mkt cap which I have been buying into. CUV one of the usual EOFY bargains on offer amongst small cap ASX companies, IMO.
CUV Price at posting:
$10.70 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)